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Background: The so called “big-big” prolactin (Prl), also known as macroprolactin is formed by Prl-immunoglobulin
(Prl-IgG) complexes and may cause elevation of serum Prl concentrations measured by standard assays, potentially
leading to unnecessary investigations and/or treatment. In our study, we have endeavoured to assess the
prevalence of macroprolactinaemia in euthyroid, regularly menstruating women with thyroid disease, as well as to
assess whether autoimmune thyroid disease may result in an increased prevalence of macroprolactinaemia.
Material and methods: We measured serum Prl in 182 regularly menstruating women aged 32.7 ± 7.5 years
(mean ± SD, range 17–46 years) who attended endocrine clinic either for investigation of non-toxic goitre (n = 86,
age 33.2 ± 7.8 years) or with autoimmune thyroid disease (n = 96, age 32.3 ± 7.2 years). Autoimmune thyroid disease
was defined as raised titre of at least one anti-thyroid antibody [anti-thyroid peroxidase (anti-TPO),
anti-thyroglobulin (anti-Tg) and/or anti-TSH-receptor (anti-TSH-R) antibodies]. All women were clinically and
biochemically euthyroid, either without or on treatment with L-thyroxine. In those with raised Prl (i.e., above
530 mIU/l) we ruled out the presence of macroprolactinaemia by polyethylene glycol (PEG) precipitation method.
Results: There was no significant age difference between women with and without autoimmune thyroid disease
(p = 0.84). Raised Prl concentrations were found in 10 women with thyroid disease (5.5%), and of those a significant
macroprolactinaemia (i.e., reduction of Prl concentrations of more than 60% after PEG precipitation) was found in 9
subjects (4.94%). There were no differences in the prevalence of macroprolactinaemia between women with
autoimmune thyroid disease (4 out of 96), and without autoimmune thyroid disease (5 out of 86, p = 0.75).
Conclusions: Approximately one out of twenty women with regular menses is likely to have raised serum Prl that
is usually caused by the presence of macroprolactinaemia. Though structure of macroprolactin involves Prl-IgG
complexes, there is no evidence that autoimmune thyroid disease is associated with raised prevalence of
macroprolactinaemia.
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The so called “big-big” prolactin (Prl), also known as
macroprolactin is formed by Prl-immunoglobulin (Prl-
IgG) complexes and may cause elevation of serum Prl
concentrations measured by standard assays, potentially
leading to unnecessary investigations and/or treatment
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distribution, and reproduction in any mediumto cases where concentration of “big-big” Prl exceeds
60% of total serum Prl concentration [2].
It is well proved that autoimmune thyroid disease is
often associated with other autoimmune conditions. For
instance pituitary antibodies can be observed in about
20% of cases of autoimmune thyroid disease [3]. Further-
more, autoimmune thyroid disease, and Hashimoto thyr-
oiditis in particular, increases the likelihood of fertility
problems and/or menstrual irregularities [4,5]. As some
studies demonstrated much higher than previously
assumed prevalence of partial autoimmune pituitaryentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Prevalence of macroprolactinaemia in regularly
menstruating women with and without autoimmune
thyroid disease; p = 0.75 (non-significant)
Autoimmune thyroid disease
Yes No Together
Macroprolactinaemia - No 92 [95.8%] 81 [94.2%] 173 [95.05%]
Macroprolactinaemia - Yes 4 [4.2%] 5 [5.8%] 9 [4.95%]
Together 96 86 182 [100%]
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thus, in our study we have endeavoured to assess the
prevalence of macroprolactinaemia in euthyroid, regu-
larly menstruating women with thyroid disease, as
well as to assess whether autoimmune thyroid disease
per se may result in an increased prevalence of
macroprolactinaemia.
Material and methods
We measured serum Prl in 182 regularly menstruating
women aged 32.7 ± 7.5 years (mean ± SD, range 17–
46 years) who attended endocrine clinic either for inves-
tigation of non-toxic goitre (n = 86, age 33.2 ± 7.8 years)
or with autoimmune thyroid disease (n = 96, age 32.3 ±
7.2 years). Autoimmune thyroid disease was defined as
raised titre of at least one anti-thyroid antibody [anti-
thyroid peroxidase (anti-TPO), anti-thyroglobulin (anti-
Tg) and/or anti-TSH-receptor (anti-TSH-R) antibodies]).
Eighty eight women of this group of patients with auto-
immune thyroid disease (91.7%) were diagnosed with
Hashimoto thyroiditis, while the remaining eight (8.3%)
had a history of Graves’ disease. All women in both
groups were clinically and biochemically euthyroid, ei-
ther without or on treatment with L-thyroxine [where
39 out of 96 patients with autoimmune thyroid disease
(40.6%) received L-thyroxine]. None of these patients
received any medication that might raise Prl concentra-
tions. Cases of “stress-induced” hyperprolactinaemia
were excluded as described by Karasek et al. [7]. In those
with genuinely raised Prl (i.e., above 530 mIU/l) we ruled
out the presence of macroprolactinaemia by a polyethyl-
ene glycol (PEG) precipitation method. This method
involves precipitation of monomeric Prl-IgG complex
with 25% PEG. Concentration of Prl is assessed before
and after PEG precipitation. Significant macroprolacti-
naemia is said to be present, where Prl recovery in the
second sample is less than 40%. According to some
authors, 40–60% recovery is considered to represent, the
so called “grey zone”, where additional methods for de-
tection of macroprolactinaemia might be sometimes ne-
cessary [8,9]. The study has been approved by the Ethics
Committee of the Polish Mother’s Memorial Hospital -
Research Institute, Lodz, Poland.
Results
There was no significant age difference between women
with and without autoimmune thyroid disease (Wald-
Wolfowitz test, p = 0.84). All patients were biochemically
euthyroid (TSH – 1.32 ± 0.72 μIU/ml), with no signifi-
cant difference in TSH concentrations between the
investigated groups. Raised Prl concentrations were
found in 10 women with thyroid disease (5.5%), and of
those a significant macroprolactinaemia (i.e., reduction
of Prl concentrations of more than 60% after PEGprecipitation) was found in 9 subjects (4.94%) (Table 1).
There were no differences in the prevalence of macro-
prolactinaemia between women with autoimmune thy-
roid disease [4 out of 96 (4.16%)], and without
autoimmune thyroid disease [5 out of 86 (5.8%), p =
0.75, Fisher’s exact test].
Discussion
To the best of our knowledge, this is the first study on
the prevalence of macroprolactinaemia in biochemically
euthyroid, regularly menstruating women with non-toxic
goitre or autoimmune thyroid disease in Poland. In our
study we observed raised Prl concentration in ten out of
182 regularly menstruating women with thyroid disease,
where in 9/10 cases (i.e., 4.9% of the total), this was
caused by macroprolactinaemia. In a single case, the
presence of macroprolactinaemia could not be totally
discounted as Prl recovery fell into the “grey zone” of
40–60%. Our data, therefore demonstrate that macro-
prolactiaemia might be present in about 1/20 of re-
gularly menstruating, clinically and biochemically
euthyroid women with various forms of thyroid disease.
This observations might have significant clinical rele-
vance, given that women with thyroid disease, particu-
larly in cases of concomitant autoimmune process, are
more likely to undergo investigations, e.g., in cases of
fertility problems, miscarriages, etc. There are no Polish
data on the prevalence of macroprolactinaemia in popu-
lation of regularly menstruating women, while the data
from foreign literature are conflicting. For instance,
Bjøro et al. [10] report macroprolactinaemia in only
0.2% of healthy, regularly menstruating women and in
0.02% of healthy men, while other studies report much
higher prevalence of macroprolactinaemia. For instance,
Hattori et al. [11] report prevalence of macroprolactinae-
mia in 3.86% of healthy, regularly menstruating women
and in 3.13% of healthy men, while according to the re-
cent Hungarian study, the prevalence of macroprolacti-
naemia was about 1.5% among 131 healthy blood donors
(50 men) [12].
In keeping with the data of Kavanagh-Wright et al.
[13], we failed to find an increased prevalence of macro-
prolactinaemia among women with autoimmune thyroid
disease. An explanation for these findings may be offered
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when the animals were injected with phosphorylated
Prl usually confined to within the pituitary [14]. The
authors speculate that some form of asymptomatic
hypophysitis, possibly of viral origin, could be asso-
ciated with leaking of pituitary phosphorylated Prl into
the systemic circulation. The usually sequestered phos-
phorylated protein might then induce antibodies to
Prl, which react with the hormone to form macropro-
lactin molecules. Thus, this would be a different mech-
anism from the one involved in generation of thyroid
autoantibodies.
In conclusion, we report that approximately one
out of 20 euthyroid women with regular menses and
either goitre or autoimmune thyroid disease is likely
to have raised serum Prl that is almost exclusively
caused by the presence of macroprolactinaemia.
Though structure of macroprolactin involves Prl-IgG
complexes, we have found no evidence that auto-
immune thyroid disease is associated with raised
prevalence of macroprolactinaemia.
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